Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

PHASE3CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Severe Hemophilia B
Interventions
DRUG

Factor IX (rFIXFc)

DRUG

rFIX

Trial Locations (51)

Unknown

Research Site, Phoenix

Research Site, Sacramento

Research Site, Aurora

Research Site, Chicago

Research Site, Indianapolis

Research Site, East Lansing

Research Site, Philadelphia

Research Site, Pittsburgh

Research Site, Seattle

Research Site, Camperdown

Research Site, Adelaide

Research Site, Perth

Research Site, Brussels

Research Site, Leuven

Research Site, Campinas

Research Site, Calgary

Research Site, Toronto

Research Site, Montreal

Research Site, Vancouver

Research site, Beijing

Research Site, Guangzhou

Research Site, Shanghai

Research Site, Tianjin

Research Site, Lyon

Research Site, Marseille

Research Site, Berlin

Research Site, Bonn

Research Site, Pokfulam

Research Site, Shatin

Research Site, Ludhiana

Research Site, Vellore

Research Site, Bangalore

Research Site, Pune

Research Site, Florence

Research Site, Milan

Research Site, Kasihara-City

Research Site, Kawasaki

Research Site, Kitakyushu

Research Site, Nagoya

Ressearch Site, Suginami-ku

Research Site, Tokyo

Research Site, Lodz

Research Site, Warsaw

Research Site, Moscow

Research Site, Saint Petersburg

Research Site, Johannesburg

Research Site, Cape Town

Research Site, Malmo

Research Site, Stockholm

Research Site, Cambridge

Research Site, London

Sponsors
All Listed Sponsors
collaborator

Swedish Orphan Biovitrum

INDUSTRY

lead

Bioverativ Therapeutics Inc.

INDUSTRY